Matoke Holdings Ltd (MHL) is a British biotechnology SME developing its proprietary Reactive Oxygen® technology as a ground-breaking antimicrobial for wound care and infection control. Our mission is to find effective, safe, scalable and practical solutions which can be delivered in a short timescale to meet the global threat of antibiotic resistance and improve patient outcomes/ lives. Our experienced management team and exceptional scientific leaders are working in partnership with world-leading researchers at British universities and teaching hospitals to develop innovative antimicrobial products, both medicinal/pharmaceutical and medical device, from discovery through to manufacture, regulatory approval and early clinical use.